Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Chugai Pharmaceutical: Navigating Patent Cliffs & Expanding Oncology Growth

Chugai Pharmaceutical’s stable share price, disciplined portfolio and strategic market‑access tactics position it to navigate upcoming patent cliffs while expanding oncology and non‑oncology growth.

Lisa Martinez

19/02/2026, 19:24

4 minutes to read

Sanofi’s 2026 Strategy: IBD Breakthrough, GCC Expansion and RSV Vaccine Push

Sanofi’s Phase 2b duvakitug data boost IBD prospects, a Hyderabad GCC expansion cuts costs, and new RSV vaccine Beyfortus targets a $2.8 billion market. Click to see how these moves could generate $1.1 billion annual revenue.

Lisa Martinez

18/02/2026, 21:47

4 minutes to read

Alnylam Beats Q4 2025 Forecasts, Raises 2026 Guidance Amid Patent‑Cliff Challenges

Alnylam’s Q4 2025 earnings beat forecasts, driven by Onpattro sales, a solid pipeline, and value‑based pricing—yet patent cliffs and rising competition pose risks to future growth.

Lisa Martinez

16/02/2026, 02:23

4 minutes to read

Sanofi Names Merck Executive Belén Garijo as CEO to Drive Growth, Mitigate Patent Risks

Sanofi’s CEO change to Belén Garijo signals a fresh strategy to navigate patent cliffs, boost its vaccine and oncology pipeline, and seize M&A opportunities for sustained growth.

Lisa Martinez

15/02/2026, 18:11

4 minutes to read

Sanofi’s New CEO Drives Vaccine Expansion & Rare‑Disease Investment to Secure Growth

Sanofi’s new CEO, strategic vaccine acquisition, and rare‑disease investment create a growth roadmap that offsets patent cliffs and boosts margins.

Lisa Martinez

14/02/2026, 23:39

4 minutes to read

Astellas Settles Patent Dispute with Zydus, Safeguarding $1.2B Myrbetriq Revenue

Read how Astellas’ $120 M settlement with Zydus keeps Myrbetriq’s patent strong, defends pricing, and protects future revenue.

Lisa Martinez

14/02/2026, 08:15

4 minutes to read

WuXi AppTec Upgraded: Strong Revenue Growth, Biologics Expansion Boosts Outlook

WuXi AppTec’s analyst upgrade signals strong growth potential in its chemistry and biologics services, with a new target price of HK$157.07 and a projected 12.4% revenue increase for FY 2025.

Lisa Martinez

13/02/2026, 17:36

4 minutes to read

Hikma Secures Saudi Deal to Launch Generic Ozempic, Targeting $43M+ MENA Revenue

Hikma Pharma partners with OneSource to launch a cheaper generic Ozempic in Saudi Arabia, targeting a booming MENA diabetes market and unlocking $43M+ in annual revenue.

Lisa Martinez

13/02/2026, 02:38

3 minutes to read

Thermo Fisher Raises $3.8B in Senior Notes to Fuel Life‑Science Innovation

Thermo Fisher’s $3.8 B senior‑notes raise fuels expansion, R&D, and strategic M&A, strengthening its edge in a competitive life‑sciences market.

Lisa Martinez

13/02/2026, 00:49

4 minutes to read

Neurocrine Biosciences Q4 2025: 29% Revenue Surge, 67% EPS Rise, & Future Growth Plans

Neurocrine Biosciences reports 29 % Q4 revenue growth driven by Nexvia launch, strong EPS lift, and a strategic roadmap to beat patent cliffs and boost 2026 earnings.

Lisa Martinez

12/02/2026, 19:20

4 minutes to read

Newer articles Older articles